ESMO Events 2025

Meetings opens in new tab/window | ESMO opens in new tab/window

Welcome to our ESMO Virtual Congress site where we showcase the very best from ESMO's flagship portfolio.

ESMO Breast Cancer Congress 2025 opens in new tab/window

Join us at this focused event that will bring together international experts in the field to explore the latest innovations, discuss cutting-edge treatments and collaborate on strategies to improve patient outcomes.

We aim to provide fresh insights into the most recent advancements in breast cancer diagnosis, treatment and survivorship, by offering a comprehensive overview of the current landscape of breast cancer care.

Share experiences, exchange ideas and forge meaningful collaborations with renowned experts in the field.

Below a collection of papers recently published in ESMO’s premier journals carefully selected to reflect the themes of the meeting.

Annals of Oncology

• Prognostic value of residual disease (RD) biology and gene expression changes during the neoadjuvant treatment in patients with HER2-positive early breast cancer (EBC)☆ opens in new tab/window A. Fernandez-Martinez, M. Tanioka, S.G. Ahn, P. Zagami, T. Pascual, M. Rediti, G. Tang, K.A. Hoadley, D. Venet, N.U. Rashid, P.A. Spears, S. Di Cosimo, E. de Azambuja, A. Choudhury, P. Rastogi, M.N. Islam, J. Cortes, A. Llombart-Cussac, S.M. Swain, C. Sotiriou, A. Prat, C.M. Perou, L.A. Carey

• TNBC-DX genomic test in early-stage triple-negative breast cancer treated with neoadjuvant taxane-based therapy☆ opens in new tab/window M. Martín, S.R. Stecklein, O. Gluz, G. Villacampa, M. Monte-Millán, U. Nitz, S. Cobo, M. Christgen, F. Brasó-Maristany, E.L. Álvarez, I. Echavarría, B. Conte, S. Kuemmel, C. Bueno-Muiño, Y. Jerez, R. Kates, M. Cebollero, C. Kolberg-Liedtke, O. Bueno, J.Á. García-Saenz, F. Moreno, E.-M. Grischke, H. Forstbauer, M. Braun, M. Warm, J. Hackmann, C. Uleer, B. Aktas, C. Schumacher, R. Wuerstleins, M. Graeser, C. zu Eulenburg, H.H. Kreipe, H. Gómez, T. Massarrah, B. Herrero, L. Paré, U. Bohn, S. López-Tarruella, A. Vivancos, E. Sanfeliu, J.S. Parker, C.M. Perou, P. Villagrasa, A. Prat, P. Sharma, N. Harbeck

ESMO Open

• Differential benefit of adjuvant everolimus according to endocrine therapy backbone in the randomized UNIRAD trial opens in new tab/window M. Saint-Ghislain, S. Chabaud, F. Dalenc, D. Allouache, D. Cameron, M. Martinez, J. Grenier, P. Barthelemy, M. Brunt, L. Kaluzinski, A. Mailliez, E. Legouffe, A.-C. Hardy-Bessard, S. Giacchetti, M.-A. Mouret-Reynier, J.-L. Canon, J. Bliss, J. Lemonnier, F. Andre, T. Bachelot, P. Cottu

• Refining prognostic tools for luminal breast cancer: genetic insights and comprehensive analysis opens in new tab/window L.A. Sinberger, T. Zahavi, N. Keren-Khadmy, Y. Dugach, A. Sonnenblick, M. Salmon-Divon

Immuno-Oncology and Technology

• Assessment of CD73 activity in breast cancer-derived small extracellular vesicles: application to monitoring of patients’ responses to immunotherapy opens in new tab/window T.L. Whiteside, S. Sehra, T. Chadderton, M. Guha, M.C. Stubbs, C. Timmers, E.K. Jackson

• Potentiating intratumoral therapy with immune checkpoint inhibitors: shifting the paradigm of multimodality therapeutics opens in new tab/window B.E. Nelson, A. Naing, S. Fu, R.A. Sheth, R. Murthy, S. Piha-Paul

ESMO Real World Data and Digital Oncology

• Clinical decision impact of HER2DX, an algorithm-powered genomic diagnostic in early-stage HER2-positive breast cancer: results from a prospective real-world study opens in new tab/window O. Martínez-Sáez, M. Tapia, M. Marín-Aguilera, E. Hernández-Illán, C. Tébar, A.I. Martinez-Puchol, P. Jares, S. Marín-Liébana, A. Magro, J.A. Puig-Butille, L. Palomar, E. Sanfeliu, M.T. Martinez, M.V. Losada, C. Hernando, B. Adamo, V. Iranzo, T. Pascual, A. Pouptsis, F. Schettini, A. Santaballa, B. Conte, M.D. Torregrosa, F. Brasó-Maristany, B. Walbaum, R. Gómez-Bravo, O. Burgués, I.G. Fructuoso, I. Garrido-Cano, E. Seguí, L. Paré, M. Muñoz, E. Carcelero, J. Sànchez, P. Villagrasa-González, W. Buckingham, A. Prat, G. Villacampa, N. Chic, P. Rivera, A. Rezqallah, C. Saura, S. Escrivà, B. Bermejo, A. Lluch, A. Llombart, J.M. Cejalvo

• Health care policies, drug costs, and time toxicities in biologics for HER2-positive breast cancer: cost minimization analysis of direct and indirect costs opens in new tab/window J.L. Low, R.S.J. Wong, Z.Y. Chan, S.C. Lee

ESMO affiliated journals

• An international Phase IV field study - psychometric properties of the updated module on assessing quality of life of patients with breast cancer EORTC QLQ-BR42 opens in new tab/window Vesna Bjelic-Radisic, Fatima Cardoso, Joachim Weis, Katarzyna Pogoda, Juan Ignacio Arraras, Elfriede Greimel, Andrew Bottomley, David Cameron, Etienne Brain, Sue Hartup, René Aloisio da Costa Vieira, Nicolette Hoefnagels, Chi-Cheng Huang, Omar Shamieh, Monica Pinto, Yared Belete Belay, Samantha Serpentini, Eveline Bleiker, Manjunath Nookala Krishnamurthy, Akihiko Shimomura, Elisabeth C. Sturm-Inwald, Mikiyas Amare Getu, Brigitte Bliem, Guro Astrup, Ofir Morag, Yuichiro Kikawa, Karin Kuljanic, Nora Nevries, Mirjam Sprangers, Neil K. Aaronson, Parisa Sinai, Krzysztof Tomaszewski, Razvan Galalae, Thierry Conroy, Francois Duhoux, Wei-chu Chie, Galina Velikova, on behalf of the EORTC Quality of Life Group and Breast Cancer Group

• Updated efficacy and safety of HLX02 versus reference trastuzumab in metastatic HER2-positive breast cancer: A randomized phase III equivalence trial opens in new tab/window Binghe Xu, Qingyuan Zhang, Tao Sun, Wei Li, Yue'e Teng, Xichun Hu, Igor Bondarenko, Hryhoriy Adamchuk, Liangming Zhang, Dmytro Trukhin, Shusen Wang, Hong Zheng, Zhongsheng Tong, Yaroslav Shparyk, Futang Yang, Haoyu Yu, Jing Li, Qingyu Wang, Jun Zhu, HLX02-BC01 Investigators

• Current controversies in the use of Oncotype DX in early breast cancer opens in new tab/window Pier Paolo M. Berton Giachetti, Ambra Carnevale Schianca, Dario Trapani, Antonio Marra, Angela Toss, Caterina Marchiò, Maria Vittoria Dieci, Oreste Davide Gentilini, Carmen Criscitiello, Kevin Kalinsky, Joseph A. Sparano, Giuseppe Curigliano

• Radioligand Therapy in Metastatic Breast Cancer: Harnessing Precision Oncology opens in new tab/window Federica Giugliano, Elisa Giordano, Laura Gilardi, Beatrice Taurelli Salimbeni, Paola Zagami, Angela Esposito, Antonio Marra, Dario Trapani, Pier Paolo Maria Berton Giachetti, Bianca Malagutti, Théophraste Henry, Desiree Deandreis, Giuseppe Curigliano, Francesco Ceci, Carmen Criscitiello

ESMO's Journal Portfolio

While diverse in nature and in content, these journals offer ESMO members and the oncology community a highly visible platform to publish important scientific studies, and a highly credible source for educational updates. Elsevier is the proud publisher of Annals of Oncology, Immuno-Oncology and Technology (IOTECH), ESMO Open, ESMO Gastrointestinal Oncology, ESMO Real World Data and Digital Oncology, ESMO Rare Cancers, and ESMO Affiliated Journals The Breast, Lung Cancer, Cancer Treatment Reviews and Clinical Lymphoma Myeloma and Leukemia.